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Purpose: The objective of the study was to compare the intraocular penetration levels of the 
newer fluoroquinolones, moxifloxacin, gatifloxacin, and levofloxacin in the rabbit’s cornea, 
aqueous humor, and conjunctiva after topical instillation.
Methods: 0.5% moxifloxacin, 0.3% gatifloxacin, and 0.5% levofloxacin were instilled in 
random sequence in both eyes of nine New Zealand White rabbits at two-minute intervals. 
Instillation was repeated every 15 minutes for a total of three drops of each fluoroquinolone 
per eye. Three additional animals had only moxifloxacin instilled bilaterally using the same 
schedule. Sixty minutes after the final instillation, the rabbits were sacrificed for determination 
of corneal, aqueous humor, and conjunctival fluoroquinolone concentrations using high-
performance liquid chromatography.
Results: Moxifloxacin achieved significantly higher concentrations than levofloxacin and 
gatifloxacin in the cornea (P = 0.0102 and P = 0.0006, respectively), aqueous humor (P = 0.0015 
and P  0.0001, respectively), and conjunctiva (P = 0.0191 and P = 0.0236, respectively).
Conclusions: 0.5% moxifloxacin eyedrops provided superior intraocular penetration in rabbits’ 
eyes compared with the two other fluoroquinolones, 0.5% levofloxacin and 0.3% gatifloxacin.
Keywords: fluoroquinolone, gatifloxacin, levofloxacin, moxifloxacin, penetration, rabbit
Introduction
Prophylactic antibiotic eye drops are routinely used to prevent postoperative 
infections. Fluoroquinolones in particular have been used extensively due to their 
excellent activity against ocular pathogens, including both Gram-positive and Gram-
negative bacteria.1,2 Selection of the most appropriate antibiotic should be based 
on considerations of pharmacodynamic and pharmacokinetic properties; namely, 
an agent with a broader spectrum, lower minimum inhibitory concentration (MIC) 
against pathogens, and better achievable concentration levels in the intraocular tissues 
should be the agent of choice to achieve optimal efficacy. However, there are few 
studies that have clearly assessed the superiority of one drug over another among the 
newer fourth-generation fluoroquinolones, including moxifloxacin and gatifloxacin, 
when used in humans.
The current study was conducted to compare the penetration levels of new 
fluoroquinolones, including the fourth-generation fluoroquinolones (moxifloxacin 
and gatifloxacin) and a third-generation fluoroquinolone (levofloxacin) in the cornea, 
aqueous humor, and conjunctiva after topical instillation in New Zealand White rabbits. 
This animal study was performed as a preliminary step toward conducting a similar 
ocular penetration study in patients scheduled for keratoplasty.Clinical Ophthalmology 2009:3 554
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Materials and methods
Twelve New Zealand White rabbits were used to determine 
the concentration levels of three topically instilled fluoro-
quinolones in the cornea, aqueous humor, and conjunctiva. 
Topical preparations of 0.5% moxifloxacin (Vegamox, Alcon 
Japan, Tokyo, Japan), 0.3% gatifloxacin (Gatiflo, Senju 
Pharmaceuticals, Osaka, Japan) and 0.5% levofloxacin 
(Cravit, Santen Pharmaceuticals, Osaka, Japan) were 
obtained from the respective manufacturers.
The rabbits were randomly assigned to four treatment 
groups in accordance with the analytical method reported by 
Diamond and colleagues and Yamada and colleagues.3–5 One 
drop of each topical preparation was instilled in both eyes of 
each animal at two-minute intervals (Figure 1). In group 1, 
moxifloxacin was instilled first, followed by gatifloxacin 
two minutes later, and finally, levofloxacin after another two 
minutes. In group 2, gatifloxacin was instilled first, followed by 
levofloxacin, then moxifloxacin, and in group 3, levofloxacin 
was instilled first, followed by moxifloxacin, then gatifloxacin. 
In group 4, only moxifloxacin was instilled to compare 
the concentration levels with those in animals instilled 
with three different fluoroquinolones in order to verify 
that the levels were similar. Instillation was repeated every 
15 minutes for a total of three drops of each fluoroquinolone 
per eye. Sixty (60) minutes after the final instillation, the 
rabbits were sacrificed and corneal, aqueous humor, and 
conjunctival samples were collected from each eye.
The sample concentrations of each fluoroquinolone were 
simultaneously determined by high-performance liquid 
chromatography (HPLC) at the Mitsubishi BCL laboratory. 
A HPLC system consisting of a L-7000 solvent delivery 
system (Hitachi, Tokyo, Japan), a L-7485 fluorescence 
detector (Hitachi), and a chromatography software (Scientific 
Software Inc., Pleasanton, CA, USA) was used. The elution 
was performed using TSKgel ODS-80TM column (Tosoh Inc., 
Tokyo, Japan) at 40 °C with a mobile phase of 75:25 mixture 
of pH 3.0, 0.05M phosphoric acid and acetonitrile. Flow rate 
was 0.8 mL/min and detection was by fluorescence (excitation 
290 nm, emission 470 nm) using a fluorescence detector. 
Drug concentrations were determined against a calibration 
line constructed from known aqueous drug concentrations.
Tukey’s multiple pair-wise comparison was employed 
for between-group comparisons. A P value of less than 0.05 
was considered statistically significant.
Results
A typical chromatogram is shown in Figure 2. The mean reten-
tion times of  levofloxacin, gatifloxacin, and moxifloxacin 
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Figure 1 Treatment schedule.
    2 minutes.
Abbreviations: MFLX, moxifloxacin; GFLX, gatifloxacin; LVFX, levofloxacin.Clinical Ophthalmology 2009:3 555
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were 5.089 minutes, 7.019 minutes and 9.495 minutes, 
respectively.
As shown on Table 1, in the 18 corneas of nine animals 
(excluding the moxifloxacin alone group), the mean 
concentration of moxifloxacin (12.23 ± 5.33 µg/g) was sig-
nificantly higher than either levofloxacin (7.34 ± 1.88 µg/g, 
P = 0.0102) or gatifloxacin (6.32 ± 2.47 µg/g, P = 0.0006). 
The aqueous humor of 18 eyes of nine animals demonstrated 
that moxifloxacin had a significantly higher mean concen-
tration (2.677 ± 1.094 µg/mL) compared with levofloxacin 
(1.511 ± 0.401 µg/mL, P = 0.0015) and gatifloxacin 
(1.112 ± 0.438 µg/mL, P  0.0001). In the conjunctiva 
(18 eyes of nine animals), mean moxifloxacin concentration 
(3.15 ± 1.60 µg/g) was significantly higher than either 
levofloxacin (1.77 ± 0.97 µg/g, P = 0.0191) or gatifloxacin 
(1.84 ± 0.94 µg/g,P = 0.0236). There were no statistically 
significant differences between levofloxacin and gati-
floxacin in any of the samples (cornea, aqueous humor, 
or conjunctiva).
No significant differences were observed among groups 
of different instillation order. Mean fluoroquinolone 
concentrations were comparable, regardless of the order 
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Figure 2 High-performance liquid chromatogram of moxifloxacin, levofloxacin, and gatifloxacin.
Table 1 Mean concentration of 0.5% moxifloxacin, 0.5% levofloxacin, and 0.3% gatifloxacin in the cornea, aqueous humor, and 
conjunctiva
Tissue 
 
Drug 
 
Group 1  
mean ± SD 
(n = 6)
Group 2  
mean ± SD 
(n = 6)
Group 3 
mean ± SD 
(n = 6)
Group 4 
mean ± SD 
(n = 6)
Group 1–3 
mean ± SD 
(n = 18)
P value* 
vs MFLX 
Cornea MFLX (µg/g) 7.85 ± 4.14 15.39 ± 5.88 13.46 ± 2.83 12.55 ± 3.48 12.23 ± 5.33 –
LVFX (µg/g) 7.75 ± 2.21 7.57 ± 2.38 6.71 ± 0.83 – 7.34 ± 1.88 0.0102
gFLX (µg/g) 4.64 ± 0.91 5.99 ± 1.39 8.32 ± 3.10 – 6.32 ± 2.47 0.0006
Aqueous humor MFLX (µg/mL) 2.022 ± 1.250 2.876 ± 1.169 3.022 ± 0.771 2.335 ± 0.714 2.677 ± 1.094 –
LVFX (µg/mL) 1.652 ± 0.508 1.483 ± 0.478 1.423 ± 0.225 – 1.511 ± 0.401 0.0015
gFLX (µg/mL) 0.887 ± 0.206 1.004 ± 0.236 1.407 ± 0.596 – 1.112 ± 0.438 0.0001
Conjunctiva MFLX (µg/g) 2.11 ± 1.23 3.97 ± 2.03 3.49 ± 1.14 3.07 ± 1.31 3.15 ± 1.60 –
LVFX (µg/g) 2.49 ± 1.27 1.24 ± 0.60 1.48 ± 0.38 – 1.77 ± 0.97 0.0191
  gFLX (µg/g) 1.49 ± 0.82 1.34 ± 0.58 2.61 ± 0.87 – 1.84 ± 0.94 0.0236
*Tukey’s multiple pair-wise comparison.Clinical Ophthalmology 2009:3 556
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of instillation. The mean concentrations of moxifloxacin 
in each tissue in group 4 (moxifloxacin alone) were nearly 
identical to those in groups 1, 2, and 3.
Discussion
Perioperative antibiotics should have several therapeutic 
attributes. Ideal agents should have a broad spectrum of 
antibacterial activity, high potency against pathogenic 
organisms, and favorable penetration characteristics to deliver 
the antibiotic to the target ocular tissues. It is particularly 
important to consider the ability to achieve a concentration 
well above the MIC for microorganisms. The present study 
showed that mean concentrations of moxifloxacin were 
significantly higher than the two other fluoroquinolones in 
all three intraocular sites tested. These results are compa-
rable to those previously reported by Yamada and colleagues 
and others.3–6 The concentration of each fluoroquinolone 
used in this study, however, was not uniform, given that 
the gatifloxacin preparation was a 0.3% solution, while 
moxifloxacin and levofloxacin were administrated as 0.5% 
solutions. This is because commercially available eyedrops 
were used in the study to mimic the clinical situation.
Besides the difference in concentrations of fluroquinolones 
tested, the present results can be logically explained from 
the viewpoint of the physical properties of the respective 
fluoroquinolones. Moxifloxacin is highly hydrophilic and 
lipophilic; the hydrosolubility of moxifloxacin is more than 
6%, while that of gatifloxacin and levofloxacin is 0.21% and 
1.85%, respectively. The liposolubility of moxifloxacin is 0.24 
(C-7, ð), while that of gatifloxacin and levofloxacin is 0.11 and 
0.06, respectively.7,8 Such disparities in the physical properties 
of these fluoroquinolones lead to differences in their ocular 
penetration. The corneal permeability of moxifloxacin is 
15.8 × 107 cm/sec, while that of gatifloxacin and levofloxa-
cin is 4.6 × 107 cm/sec and 6.95 × 107 cm/sec, respectively. 
Such properties of moxifloxacin are thought to be due to its 
chemical structure, which comprises a large pyrrolo-pyridine 
group chain at the C7 position of the basic quinolone structure, 
conferring hydrophilicity along with lipophilicity.7
Based on the findings from the current animal study, 
a similar clinical study using patients scheduled for kerato-
plasty is planned. The drugs used and the application schedule 
will be identical to the present study, and samples will be 
collected during surgery for drug concentration determination. 
Although animals are typically randomized into three different 
treatment groups in studies comparing three distinct eye drops, 
the present study design, in which three different eye drops are 
nearly simultaneously instilled into the animals’ eyes, offers 
the advantage that a single specimen can yield three drug 
concentrations because HPLC can distinguish the different 
drugs. Individual differences in specimen permeability can 
make it difficult to compare the concentrations of different 
eye drops using traditional study design; however, the present 
method overcomes such problems, and allows the drugs 
to be compared within one specimen.
Before proceeding to a human study, some issues that 
may limit the interpretation of the current results should 
be reviewed. Since the time to maximum concentration in 
the aqueous humor (AQTmax) differs according to each agent, 
the timing of instillation is critical.9,10  The present study may 
have missed AQTmax of one or more of the study medications. 
The second issue is whether the concentrations of other agents 
might increase as a consequence of moxifloxacin in a group 
where moxifloxacin is instilled first since there is substantial 
penetration of moxifloxacin into the intraocular tissue. The 
third issue is whether a two-minute interval is optimal, since 
some investigators recommend a five-minute interval or at 
least a three-minute interval when investigating the efficacy of 
a particular agent. Although a two-minute interval is supported 
by a report showing that concentration levels in the anterior 
chamber did not differ when steroid eye drops were instilled 
at two-minute intervals,11 the controversy remains. Our results 
also support the use of a two-minute interval, as no difference 
in concentrations was found among all four treatment groups, 
including the group which received only moxifloxacin.
Conclusion
In this study, topically applied 0.5% moxifloxacin achieved 
higher concentrations in cornea, aqueous humor and conjunctiva 
than 0.5% levofloxacin and 0.3% gatifloxacin in rabbit eyes. 
However, future penetration studies in humans as well as clini-
cal studies using patients with ocular infections would reveal 
the differences in clinical efficacy among fluoroquinolones.
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